Advertisements

Bifonazol Ramos

Quick links to important sections

Bifonazol Ramos

Advertisements
Advertisements

Method of action: Antifungal Broad Spectrum

Treatment option: Hyperhidrosis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Bifonazol Ramos

Property Description
Active ingredient Bifonazole (C22H18N2)
Form Cream, Gel, Solution, Ointment (Topical)
Pharmacological class Antifungal agent (Substituted imidazole)
General Purpose Resolution of superficial fungal infections
Origin Synthetic

Bifonazol Ramos is a medicinal preparation whose active substance is Bifonazole, which is classified as a synthetic, broad-spectrum antifungal agent that belongs to the substituted imidazole pharmacological class. This compound is primarily designed for the topical management of fungal skin conditions.


Identity, Composition, and Administration

The drug entity, Bifonazole, is a molecule of synthetic origin and constitutes a single-substance product. It acts as a potent antimycotic agent, confirming its core purpose is to address the biological cause of fungal disorders. Pharmacological studies recognize that the molecule's specific structure contributes to its prolonged retention in the outer layers of the skin, a characteristic that differentiates it from some earlier azole compounds. For effective delivery, Bifonazole is consistently formulated for topical administration and is available in high-level dosage form(s), including creams, gels, and solutions, utilizing various bases such as a lipid-aqueous emulsion.


General Therapeutic Purpose

The overarching purpose of Bifonazol Ramos is to resolve superficial fungal infections by leveraging the targeted mechanism of Bifonazole against the fungal pathogens. This action is achieved through chemical interference with the fungal cell's essential metabolism.

Bifonazole exhibits a unique dual mode of action, interfering with the biosynthesis of ergosterol, an indispensable component of the fungal cell membrane. The compound is clinically recognized for its ability to target both the growth and viability of the fungus, confirming its role as an important antimycotic drug, primarily used for cutaneous mycoses. This robust mechanism grants the medication both fungicidal properties (killing the organism) and fungistatic properties (halting its growth), serving as a definitive approach to clearing fungal skin disorders.

Regulatory References

  1. WHO Essential Medicines List - Antifungal medicines for skin infection
Advertisements

What side effects are possible with Bifonazol Ramos?

Possible side effects and safety information

The safety profile for topical Bifonazol Ramos is primarily characterized by localized reactions at the application site, classified according to standard regulatory frequency bands.

Officially documented adverse reactions are classified under Skin and Subcutaneous Tissue Disorders and General Disorders and Administration Site Conditions. Common reactions (occurring in 1 to 10 users in 100) include a skin burning sensation, pruritus (itching), erythema (redness), skin irritation, and skin peeling.

Less frequently (uncommon), contact dermatitis has been reported. A variety of other local effects, such as pain at the administration site, dry skin, rash, and blistering, are also documented, with their frequency classified as Not Known (cannot be estimated from available data).

Although rare, the regulatory label notes the possibility of Systemic Hypersensitivity Reactions, which are classified as serious but occurring very rarely. Most common skin reactions are noted to be generally reversible after discontinuation of treatment.

Specific safety considerations are documented for certain patient populations and co-administered substances. The use of Bifonazol Ramos is not recommended during the first trimester of pregnancy and caution is advised thereafter, based on a benefit-risk assessment. Given that it is unknown if the active substance passes into human milk, the label recommends that breast-feeding should be discontinued during treatment. Caution is also advised when the product is used concomitantly with the oral anticoagulant Warfarin, as limited data suggests the potential for an increase in the International Normalized Ratio (INR), which requires appropriate monitoring. The presence of excipients, such as cetostearyl alcohol, may also cause local skin reactions.

Advertisements

Overdose and Emergency Response

The official regulatory documents provide specific information regarding overdose for topical Bifonazole (Bifonazol Ramos), which is guided by the drug's formulation and minimal absorption into the body. This official profile addresses scenarios involving both excessive dermal use and accidental ingestion.

The regulatory assessment indicates that due to the low rate of systemic absorption following topical use, there is no risk of acute intoxication seen even after a single excessive dermal application over a large area. Acute toxicity is therefore considered unlikely to occur based on official regulatory statements. No severe systemic outcomes or unique population-specific risks are explicitly listed in the official overdose sections.

Despite the low acute risk, the official labeling mandates immediate action: a physician or healthcare professional must be consulted immediately if an overdose is suspected. This required consultation is the official guidance for when medical help must be sought. In the specific circumstance of accidental oral ingestion of the topical product, the official guidance states that no specific antidote is known. However, supportive procedural steps are documented, and routine measures such as gastric lavage should be performed as soon as possible. Overall treatment for overdose, where necessary, is described as symptomatic and supportive management.

Advertisements

Therapeutic Uses of Bifonazol Ramos

What Bifonazol Ramos Treats: Main Uses and Benefits

Bifonazol Ramos is commonly used in conditions presenting with acute or episodic manifestations caused by fungal pathogens, specifically superficial mycoses that affect the outer layers of the skin. It is applied across therapeutic domains involving common Tinea infections, such as athlete's foot (tinea pedis), ringworm (tinea corporis), and jock itch (tinea cruris), as well as cutaneous candidiasis and pityriasis versicolor. This supports the primary therapeutic goal of clearing the infection.

The medication is applied to address symptom clusters that may become disruptive, helping to manage symptoms related to physical discomfort, such as itching and the burning sensation, and the visible signs of inflammation like redness and scaling. Addressing these pronounced symptoms offers crucial symptomatic relief that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Bifonazol Ramos is relevant in clinical contexts where symptoms cluster in specific, localized areas, such as the body's folds (intertriginous areas). Its application in these common real-world scenarios supports the patient during difficult episodes and assists with maintaining functional stability in the affected area.

Quick Fact: Relief for Dermal Discomfort

Regulatory References

  1. NPS MedicineWise overview
Advertisements

Eligibility and Restrictions for Use

The use of Bifonazol Ramos is governed by strict population eligibility rules derived from official regulatory documents, establishing who may use the medicine and who is officially excluded.

Absolute Contraindications

Use is prohibited for individuals with a known hypersensitivity to the active substance, Bifonazole, or any excipients in the formulation. The medicine is contraindicated for women who are breastfeeding due to the inability to exclude a risk to the infant, and it must not be used to treat nappy rash in infants.

Restricted and Conditional Use

Age-related limitations apply to the pediatric population: use in infants and children is conditional and must be under medical supervision. For adults and older adults, standard use is generally established.

Regarding reproductive status, use is not recommended during pregnancy, particularly in the first trimester, and in women of childbearing potential who are not using contraception.

A key eligibility restriction is required for patients concurrently taking the anticoagulant warfarin, where use demands caution and monitoring of the anticoagulant effect, as documented in the label. Caution is also required for those with a history of allergic reactions to other imidazole antifungals.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Bifonazol Ramos's official regulatory profile is defined by specific pharmacokinetic interaction patterns with co-administered substances. No combinations are formally documented as absolute contraindications in the current regulatory labeling.

Documented Drug Exposure Changes

1. Interaction with Coumarin Anticoagulants

Limited data in regulatory documents suggest a possible interaction between topical Bifonazole and oral Coumarin Anticoagulants, specifically Warfarin and Acenocoumarol. This interaction is pharmacokinetic, involving the reduced clearance of the anticoagulant. The formal outcome is described as a potential increase in the International Normalized Ratio (INR), reflecting an enhanced anticoagulant effect.

Condition-Specific Constraint: The risk of this exposure-modifying interaction is explicitly stated to be greater when Bifonazole is applied to a large surface area or to broken or damaged skin, as increased systemic absorption may occur.

2. Interaction with Antacids

Co-administration of Bifonazole with oral antacids containing Aluminum hydroxide or Magnesium hydroxide is documented to reduce the absorption of Bifonazole itself. This pharmacokinetic effect may result in a lower systemic concentration of the antifungal agent.

Timing and Other Substances: No mandatory administration time-separation rules are specified in regulatory labeling for the topical formulation, nor are specific interactions with food, alcohol, or herbal products explicitly documented.

Advertisements

Mechanism of Action

Bifonazole's pharmacodynamic mechanism is characterized by a unique dual enzymatic inhibition alongside a complementary action on host tissue. The molecule primarily targets the fungal cell by acting as an inhibitor of Lanosterol 14-alpha-demethylase (CYP51) and HMG-CoA Reductase. This dual blockade interrupts the ergosterol biosynthesis pathway, leading to the depletion of necessary membrane components and the accumulation of toxic intermediate sterols. This mechanistic cascade causes irreversible structural failure and increased permeability of the fungal cell membrane, resulting in a loss of cellular integrity and function (fungicidal or fungistatic cellular consequence). Independent of this antifungal action, Bifonazole functions as a modulator of host inflammatory pathways in the peripheral skin tissue. This action involves influencing the release of local pro-inflammatory mediators, which results in the reduction of signaling within the inflammatory cascade and produces a corresponding localized physiological change. Its topical administration facilitates a high concentration gradient at the site of action, constraining potential off-target systemic activity and resulting in a strictly localized physiological effect.

Advertisements

Dosage and Administration Information

Instruction Map: How to use Bifonazol Ramos — Official Administration Guidelines


Administration Scope

Property Content
Route of administration Topical (Cutaneous Use); intended strictly for external application.
Dosing schedule Apply a small amount (pea-sized) of the 1% w/w cream thinly and gently rubbed into the affected skin area and the immediate surrounding region.
Timing in relation to meals (if applicable) Not applicable.
Preparation requirements (if applicable) The affected areas must be washed and dried thoroughly before each application.
Age-group administration rules Use in infants and children must be managed under medical supervision.
Missed-dose rules If an application is missed, it should be skipped if it is almost time for the next scheduled dose; do not double the dose to compensate.
Special procedural conditions The treated area must not be covered with occlusive bandages or dressings unless directed by a prescribing professional.

Instruction Classifications (High-Level)

Property Content
Administration method type Topical.
Frequency pattern Once daily, preferably in the evening before retiring.
Administrative basis Standardized clinical protocols.
Use-context constraints Requires pre-application skin preparation and adherence to mandated, infection-specific treatment durations.

Resulting Procedural Structure

Official step sequence:

  • The affected area must be thoroughly washed and dried.
  • The 1% cream is applied once daily (preferably at night).
  • The course must be completed over the full duration, which is typically three weeks for athlete’s foot or two to three weeks for ringworm/jock itch.

Connection to the overall use protocol (2–4 sentences): The official administration guidelines establish a standardized topical protocol for Bifonazole, emphasizing a once-daily application using a small, specified quantity of the 1% cream. This protocol dictates the exact quantity, application method, and necessary pre-application steps, ensuring the proper physical delivery of the drug. Furthermore, the instructions set the required duration of use and define specific administrative constraints, such as the need for medical supervision in pediatric patients, to standardize its application.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bifonazol Ramos

The research examining Bifonazole has been evaluated primarily through controlled clinical trials and comparative studies exploring its application for common superficial fungal infections. The findings describe group patterns and contribute to the broader evidence landscape, but study results reflect the specific conditions under which they were conducted.


Evidence for Tinea Pedis (Athlete's Foot) Research

This section summarizes the structure of Randomized Controlled Trials (RCTs) and systematic reviews that have investigated Bifonazole for use in athlete's foot, detailing the outcomes researchers measured, such as the measurement of fungal presence and symptom evolution.

The evidence for this indication comes from multiple short-term RCTs where Bifonazole was studied for conditions characterized by episodic or acute manifestations of athlete's foot. The main focus of research was on two key areas: mycological endpoints (the measurement of fungal presence confirmed by lab tests) and clinical endpoints (changes in outcomes related to physical discomfort, such as itching and scaling). Findings describe patterns observed in these studies, where measured changes in fungal presence and symptom evolution were documented during the study period. Comparative data show patterns related to measured outcomes when Bifonazole was evaluated against some other topical antifungal options.

What remains uncertain is the status of the measured fungal status. The existing body of evidence provides limited information for long-term outcomes, such as the frequency of the infection returning over observation periods longer than a few weeks after treatment concludes.


Evidence for Tinea Corporis, Tinea Cruris, and Pityriasis Versicolor

This block describes the types of controlled clinical studies that exist for Bifonazole across other common superficial mycoses, including ringworm and pityriasis versicolor, outlining the study designs and the clinical endpoints assessed.

Bifonazole was studied for conditions associated with acute or disruptive episodes of ringworm (tinea corporis), jock itch (tinea cruris), and pityriasis versicolor. Researchers monitored clinical endpoints such as the measured evolution of clinical signs and the patient-reported outcomes describing perceived discomfort. The evidence contributes to the broader evidence landscape by providing context on the patterns observed in these specific infection types. The evidence is limited because fewer large-scale systematic reviews are available, and follow-up durations were limited in many of the trials.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Bifonazol Ramos (FAQ)


Q: How quickly does Bifonazol Ramos start to work for fungus?

A: Official information does not specify the exact time to onset of action for symptom relief. However, studies show the active substance, Bifonazol, rapidly penetrates the infected skin layers. The drug's chemical properties allow it to remain in the affected skin layers for an extended time, which is consistent with its once-daily application schedule.

Q: Is Bifonazol Ramos the same as just 'Bifonazol'?

A: No, Bifonazol is the active substance (the generic drug) that works to kill the fungus. Bifonazol Ramos is a brand or trade name used to market the medicine that contains the active ingredient Bifonazol.

Q: What should I do if I accidentally swallow a little Bifonazol Ramos?

A: Regulatory documents indicate that acute intoxication is not expected if a small amount of the topical cream is inadvertently swallowed. The product is strictly for external skin application. If any unusual symptoms occur, such as dizziness or vomiting, professional medical assistance or advice should be sought.

Q: Can I use Bifonazol Ramos on my face for a fungal infection?

A: The product information states the medicine is intended strictly for external skin application. Official cautions recommend avoiding contact with sensitive areas like the face and eyes. If the cream accidentally contacts the eyes, mouth, or nose, regulatory guidance suggests rinsing the area with water immediately.

Q: What are the signs that Bifonazol Ramos is starting to work?

A: Clinical studies track improvement through two key areas: the reduction of fungal presence and the improvement of clinical endpoints. The expected physical changes monitored in studies relate to a reduction in discomfort, such as a decrease in itching and scaling of the infected area.

Q: How should I store Bifonazol Ramos products?

A: Official storage precautions require that the product be stored below 30 C in a dry place. It must also be protected from direct sunlight and kept strictly out of the sight and reach of children.

Q: How long does Bifonazol Ramos last once the package is opened?

A: The medicine has a limited shelf life once the tube is first opened. This period is typically 6 to 16 months (depending on the specific local product label) after opening, and should not be used past the product's printed expiry date.

Q: Can I put makeup or lotion over Bifonazol Ramos once it's applied?

A: Some official resources advise that if another topical product, such as a moisturizer, is needed on the same area, the Bifonazol cream should be applied first. You can then allow a short period of time (e.g., 15 minutes) for it to absorb before applying the other product.

Q: Does using Bifonazol Ramos cure the fungus permanently?

A: The purpose of the medicine is to resolve existing fungal infections. However, the available research provides limited information on long-term outcomes regarding how frequently the infection may return (recur) after the full course of treatment is concluded.

Q: What should I do if my symptoms get worse while using Bifonazol Ramos?

A: If symptoms worsen, do not improve after a certain period of use (usually a few days to a week), or if new issues like blistering or broken skin develop, it is recommended to discontinue the application and consult a healthcare professional for guidance.

Q: Can Bifonazol Ramos be used near the groin area?

A: Yes, Bifonazol is indicated for the treatment of Tinea Cruris, commonly known as jock itch, which is a fungal infection affecting the groin area. The medicine is for external application to the affected skin.

Q: Do you have to cover the treated area after applying Bifonazol Ramos?

A: Official instructions specify that the treated area must not be covered with occlusive bandages or dressings. This should only be done if you are specifically directed to do so by a prescribing healthcare professional.

Q: Can Bifonazol Ramos be used for nail fungus?

A: Bifonazol cream is typically not recommended for the treatment of nail or scalp infections. These conditions usually require specialized formulations or oral treatments due to the difficulty of the active substance penetrating the nail plate or hair follicles.

Q: Is Bifonazol Ramos a broad-spectrum antifungal?

A: Yes, the active substance, Bifonazole, is officially classified as a synthetic, broad-spectrum antifungal agent. This means it is effective against a wide range of common fungal pathogens, including dermatophytes, yeasts, and molds.

Q: Is Bifonazol Ramos a cream, a powder, or something else?

A: Bifonazol is a versatile active substance formulated for topical administration. It is most commonly available as a cream, but may also be found in other dosage forms, such as a gel or solution, depending on the specific product line.

Q: Is Bifonazol Ramos safe to use during pregnancy? (informational)

A: According to official product information, use is not recommended during the first trimester of pregnancy. Any use beyond the first trimester requires caution and should be discussed with a healthcare professional.

Q: Can children use products containing Bifonazol Ramos?

A: Use in infants and children is conditional and is required to be under the supervision of a healthcare professional. The medicine is also specifically contraindicated (prohibited) for use in treating nappy rash in infants.

Q: What happens if I stop using Bifonazol Ramos too soon?

A: Official instructions emphasize that the full duration of the prescribed treatment course is necessary (for example, three weeks for athlete’s foot). Stopping too soon risks the infection not being completely cured, which may lead to it coming back.

Q: Does sun exposure affect how Bifonazol Ramos works?

A: There are no specific regulatory warnings about direct sun exposure to the application site during treatment. However, the product itself should be stored correctly, protected from direct sunlight, to maintain its stability.

Advertisements

How should Bifonazol Ramos be stored and disposed of?

Storage and Disposal of Bifonazol Ramos

Official Storage Requirements

Constraint Regulatory Requirement
Temperature Limit Store the cream below 30 C.
Protection Store in a cool, dry place and protect from direct sunlight.
Child Safety Must be kept out of the sight and reach of children.
Packaging Store in the original carton until immediately before use.

Stability and Disposal Mandates

Unused or expired Bifonazol cream must be managed according to specific regulatory mandates concerning its stability and final disposal.

  • Post-Opening Shelf Life: The product has a limited period of use, typically up to 16 months after first opening the tube.
  • Disposal Restriction: The medicine should not be disposed of via wastewater or household waste to prevent environmental contamination.
  • Handling: Users must ask a pharmacist for proper disposal instructions for any medicines that are no longer required.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bifonazol Ramos found in:

A-Z Index: